Share on StockTwits

HeartWare International (NASDAQ:HTWR) Insider Jeffrey Larose sold 2,179 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $81.51, for a total value of $177,610.29. Following the sale, the insider now directly owns 822 shares of the company’s stock, valued at approximately $67,001. The transaction was disclosed in a document filed with the SEC, which is available at this link.

A number of analysts have recently weighed in on HTWR shares. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of HeartWare International in a research note on Friday, August 1st. They now have a $125.00 price target on the stock, down previously from $128.00. Separately, analysts at Leerink Swann cut their price target on shares of HeartWare International from $120.00 to $105.00 in a research note on Friday, August 1st. Finally, analysts at Zacks upgraded shares of HeartWare International from a “neutral” rating to an “outperform” rating in a research note on Friday, August 1st. They now have a $105.70 price target on the stock. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. HeartWare International currently has a consensus rating of “Buy” and an average price target of $108.97.

Shares of HeartWare International (NASDAQ:HTWR) traded down 0.30% during mid-day trading on Friday, hitting $80.76. The stock had a trading volume of 25,447 shares. HeartWare International has a 52 week low of $69.31 and a 52 week high of $105.84. The stock has a 50-day moving average of $85.18 and a 200-day moving average of $90.22. The company’s market cap is $1.373 billion.

HeartWare International (NASDAQ:HTWR) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.45. The company had revenue of $70.10 million for the quarter, compared to the consensus estimate of $67.01 million. Analysts expect that HeartWare International will post $-2.20 EPS for the current fiscal year.

Heartware International, Inc (NASDAQ:HTWR) develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure.

Receive News & Ratings for HeartWare International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartWare International Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.